KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Non-Current Assets (2016 - 2025)

CRISPR Therapeutics AG's Other Non-Current Assets history spans 11 years, with the latest figure at $7.6 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 33.77% year-over-year to $7.6 million; the TTM value through Dec 2025 reached $7.6 million, down 33.77%, while the annual FY2025 figure was $7.6 million, 33.77% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $7.6 million at CRISPR Therapeutics AG, down from $24.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $24.3 million in Q3 2025 and bottomed at $7.6 million in Q4 2025.
  • The 5-year median for Other Non-Current Assets is $11.8 million (2023), against an average of $13.5 million.
  • The largest annual shift saw Other Non-Current Assets surged 234.14% in 2021 before it crashed 33.77% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $16.9 million in 2021, then tumbled by 31.21% to $11.6 million in 2022, then decreased by 0.38% to $11.6 million in 2023, then dropped by 0.62% to $11.5 million in 2024, then plummeted by 33.77% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Other Non-Current Assets are $7.6 million (Q4 2025), $24.3 million (Q3 2025), and $8.0 million (Q2 2025).